Deyang Yu

Deyang Yu

Auto-generated profile, based on publicly available information

Deyang Yu

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LZLong Zhang
Long Zhang
CHCharbel S. Hobeika
Charbel S. Hobeika
DKDamir Khabibullin
Damir Khabibullin
DYDeyang Yu
Deyang Yu
HFHarilaos Filippakis
Harilaos Filippakis
EHElizabeth P Henske
Elizabeth P Henske
Chromophobe (Ch) renal cell carcinoma (RCC) arises from the intercalated cell in the distal nephron. There are no proven treatments for metastatic ChRCC. A distinguishing characteristic of ChRCC is strikingly high levels of reduced (GSH) and oxidized (GSSG) glutathione. Here, we demonstrate that ChRCC-derived cells exhibit higher sensitivity to ferroptotic inducers compared with clear-cell RCC. ChRCC-derived cells are critically dependent on cystine via the cystine/glutamate antiporter xCT to maintain high levels of glutathione, making them sensitive to inhibitors of cystine uptake and cyst(e)inase. Gamma-glutamyl transferase 1 (GGT1), a key enzyme in glutathione homeostasis, is markedly suppressed in ChRCC relative to normal kidney. Importantly, GGT1 overexpression inhibits the proliferation of ChRCC cells in vitro and in vivo, suppresses cystine uptake, and decreases levels of GSH and GSSG. Collectively, these data identify ferroptosis as a metabolic vulnerability in ChRCC, providing a potential avenue for targeted therapy for these distinctive tumors.